Board summary
Key figures
35,343
Registered population
60.7% aged 18–64
16.2%
Aged 65+
ICB 19.9% · England 17.9%
15.3%
Ethnic minority (non-White)
4.8% Asian · England 9.6%
37.9%
In IMD quintile 1
ICB 17.1% · England 21.0%
~10,635
Core20 residents (est.)
Resident basis; registered basis ~13,252 · see page 3
5,238
Hypertension register
-0.15% in 3 yrs · England +5.60%
323
SMI register
11.4% of Medway (LAD)'s
666
COPD register
Reviews -0.06% in 3 yrs
Forecast to 2030
5,498
Hypertension patients, 2030
+260 on today
71.0%
QRISK ≥20% on statins, 2030
+5.20pp over 3 yrs
3.4%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Hypertension blood pressure control trails comparators.
Treatment to target is 59.5% (Medway 67.5%, ICB 67.7%, England 70.3%) and 62.8% in patients aged 80+, which may reflect titration gaps to audit.
Asthma annual reviews and youth recording lag.
Annual reviews fell 7.1% (England +4.4%) to 61.5%, leaving about 803 patients unreviewed, while youth second-hand smoke recording is 64.7% (England 78.8%).
Heart failure reviews and diabetes statins lead.
Heart failure reviews rose +70.9% (England +8.7%) to 83.8% (England 78.5%), and statin prescribing in diabetes without CVD reached 76.8% (England 73.2%).
Population, age and ethnicity
Aspire Medical PCN has a younger population with 23.0% aged 0-17
Across 35,343 registered patients, Aspire Medical PCN has a younger age structure: 23.0% (8,141 patients) are aged 0-17, above Medway (LAD) (21.6%), NHS Kent and Medway ICB (20.7%), and England (19.6%), while 16.2% (5,736 patients) are aged 65+, below Medway (LAD) (17.9%), the ICB (19.9%), and England (17.9%). Resident Census estimates (usual residents, not registered patients) show 15.3% ethnic minority residents, including 6.5% Black / African / Caribbean / Black British, above Medway (LAD) (5.6%), the ICB (3.1%), and England (4.2%).
Age profile
65+: ICB 19.9%, England 17.9%
Ethnicity
Older people · falls rows are Medway (LAD) local-authority (LA) data, not PCN
| Measure | Local | South East | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Medway LA) | 1,507 | 2,018 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 76.9% | 82.2% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 47.1% | 57.8% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Medway LA) | 740 | 981 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Medway LA) | 19.5 | 14.0 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 deprivation reaches 37.9% PCN-wide, concentrated sharply across an 89.2 pp practice spread
Aspire Medical PCN averages an IMD decile of 4.0 (Medway 4.9 decile, NHS Kent and Medway ICB 5.4 decile, England 5.5 decile). Core20 patients represent 37.9% of registered patients, above Medway (23.1%), NHS Kent and Medway ICB (17.1%) and England (21.0%). Practice shares span 89.2 pp, from 6.7% at St. Werburgh Med.practice to 95.9% (7,999 estimated patients) at The Kings Family Practice, followed by Stonecross And West Drive Surgery at 38.8% (2,981 estimated patients).
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
323
SMI register
0.87% recorded prevalence
258
Learning disability register
0.69% recorded prevalence
26
Care homes, 749 beds
In the PCN catchment
8.9%
Provide unpaid care
Medway (LAD), Census 2021
The PCN records 258 learning disability patients (0.7%; Medway (LAD) 0.7%, ICB 0.6%, England 0.6%) and 323 severe mental illness patients (0.9%; Medway (LAD) 0.9%, ICB 0.9%, England 1.0%). The catchment contains 26 care homes with 749 beds, though registered occupancy is unconfirmed.
Severe mental illness: physical health checks
SMI physical health checks fell: BMI recording fell 8.9 pp (England +5.1 pp) to 71.5% (England 82.1%), and blood pressure fell 6.8 pp (England +4.4 pp) to 72.4% (England 83.4%), which could reflect routine recall gaps.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
5,238
Hypertension register
−0.15%
Register growth, 3 yrs
Medway (LAD) +3.74% · England +5.60%
+1.78pp
BP control, under 80
≤140/90 · −7.52pp aged 80+
+260
More patients by 2030
Forecast 5,498 (14.06%)
Hypertension case-finding and control
Hypertension prevalence is 14.1% (5,238 patients), below Medway (LAD) (15.4%) and England (15.2%). Recent blood pressure monitoring is 81.3% (England 90.0%), while treatment to target is 59.5% (England 70.3%). For patients aged 80 and over, blood pressure control fell 10.7% over three years (England +2.2%) to 62.8% (England 81.2%), and under-80 control is 58.9% (England 67.8%). Slower monitoring and control could reflect recall gaps to verify locally.
Lipids and statins
Patients with QRISK ≥ 20% on lipid-lowering therapy reach 59.0% (England 63.6%), though coverage rose +9.7% over three years (England +6.2%). Statin prescribing in diabetes without CVD reached 76.8% (England 73.2%).
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 57,789 | £1.90 | £1.90 | £1.86 | £109,799 |
| Cardiovascular (all), 2025 | 71,592 | £3.08 | £3.57 | £3.33 | £220,503 |
In 2026, the PCN prescribed 57,789 lipid-regulating drug items at £1.90 per item, compared with £1.86 in England and £1.90 in NHS Kent and Medway ICB. This is £2,312 more than at England's unit cost, across 57,789 items.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
−7.13%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
−6.09%
Asthma prevalence, PCN 3-yr % change
Asthma register prevalence is 6.0% across 2,084 patients (England 6.6%, Medway (LAD) 6.0%). Annual asthma reviews fell 7.1% over three years (England +4.4%) to 61.5% (England 65.7%), leaving about 800 patients unreviewed. Furthermore, recorded second-hand smoke exposure in asthma patients aged 6-19 is 64.7% (England 78.8%). Meanwhile, the COPD register has 666 patients (1.8% prevalence, England 1.9%), and annual COPD reviews stand at 74.8% (England 76.4%). These review shortfalls may reflect recall capacity constraints to verify locally.
Cancer register and children's immunisation
Cancer register prevalence is 3.2% with 1,189 patients (England 3.8%). In childhood immunisation, Q1 2025/26 coverage trails the 95.0% target: 6-in-1 at 12 months is 84.6% (England 91.0%), while age-5 MMR drops 12 pp from 91.2% at dose 1 to 79.2% at dose 2 (England 82.8%), 15.8 pp below target alongside 4-in-1 boosters (79.2%). This drop could reflect follow-up barriers before school entry.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.6%
Kent and Medway ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~1,630
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Kent and Medway ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Breast | 82.1% | 85.4% | 23% | 1,509 |
| Prostate | 54.4% | 53.2% | 37% | 1,435 |
| Lung | 29.4% | 33.8% | 21% | 1,109 |
| Bowel | 48.2% | 47.0% | 29% | 1,013 |
| Skin cancer | 87.5% | 87.8% | 23% | 562 |
Across NHS Kent and Medway ICB in 2022, 55.6% of staged cancers (4,661 of 8,384) were diagnosed at stage 1 or 2, compared with 55.3% in England, sitting 19.4 pp below the 75.0% national ambition by 2028, while 63.6% had a known stage (England 67.0%). This rose +2.2 pp from 53.4% in 2013, leaving 1,627 extra early-stage diagnoses needed annually across the ICB, reflecting wider system staging rather than PCN performance. Slower PCN cancer register growth (+2.7% versus +9.0% in England) is consistent with potential diagnostic or recording gaps, so clinical coding and referral pathways should be prioritised.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In provisional Jul 2026 data, Medway NHS Foundation Trust achieved 99.6% on the 31-day standard (standard 96.0%; England 92.5%) and 77.8% on 28-day faster diagnosis (standard 75.0%; England 79.3%), while 62-day waits reached 81.6% (standard 85.0%; ICB 75.9%; Maidstone and Tunbridge Wells NHS Trust 87.4%; England 71.2%). Diagnostic 6-week waits were 0.7% for MRI and 0.0% for CT (England 21.4% and 9.9%), though echocardiography reached 36.6% (England 28.5%; Maidstone and Tunbridge Wells NHS Trust 2.6%). Provider metrics reflect acute trust performance rather than PCN delivery. Local acute cancer pathways largely meet operational standards, focusing PCN priorities on prompt initial referral.
| Pathways within standard (%) | Medway | Maidstone and Tunbridge Wells | Mid and South Essex | Kent and Medway ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 77.77 | 81.78 | 67.45 | 76.78 | 79.32 |
| 31-day treatment (96%) | 99.62 | 98.35 | 81.88 | 95.84 | 92.50 |
| 62-day referral to treatment (85%) | 81.64 | 87.43 | 50.25 | 75.93 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Medway | Maidstone and Tunbridge Wells | Mid and South Essex | England |
|---|---|---|---|---|
| MRI | 0.68 | 0.92 | 23.35 | 21.40 |
| CT | 0.00 | 0.51 | 6.07 | 9.92 |
| Echocardiography | 36.62 | 2.57 | 65.05 | 28.48 |
| Colonoscopy | 1.88 | 19.80 | 64.09 | 30.83 |
| Gastroscopy | 3.32 | 24.03 | 59.76 | 29.02 |
| All 15 DM01 tests | 14.20 | 6.42 | 41.54 | 23.14 |
| Community services activity | Kent residents | Kent and Medway ICB |
|---|---|---|
| Care contacts | 210,170 | 254,055 |
| Referrals | 59,360 | 68,085 |
| Patients with a contact | 60,605 | 72,060 |
Community services (residents of Kent), Jun 2026 (provisional). In provisional Jun 2026 Community Services Data Set records, adults aged 65 and over accounted for 62% of community contacts among Medway borough residents (26,985 of 43,510 contacts), describing borough-level activity rather than PCN performance. This concentration of community activity among older residents could offer opportunities to align shared post-diagnostic care, though local pathway integration has not been verified.
Practice variation and patient experience
Practice variation and patient experience
In 2025/26, all five practices achieved 100.0% in the QOF clinical domain (England 97.1%). Overall achievement reached 96.8% at St. Werburgh Med.practice and 98.9% at Marlowe Park Medical Ctr. (England 92.5%). Vaccination and immunisation achievement spans an 18.2 pp range, from 71.9% at St. Werburgh Med.practice to 90.0% at Marlowe Park Medical Ctr.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Kings | 90 | 95.9 | 54.4% | 77.8% | 72.7% |
| London Road | 114 | 13.8 | 35.4% | 77.7% | 68.2% |
| Marlowe Park | 92 | 18.6 | 42.2% | 71.2% | 67.4% |
| Stonecross And | 87 | 38.8 | 28.9% | 77.1% | 63.2% |
| St. Werburgh Med. | 102 | 6.7 | 35.3% | 86.8% | 55.9% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Sixteen of 25 tracked three-year measures trail England despite strong review gains
Across 25 tracked three-year measures, 16 trail England. Routine monitoring for severe mental illness fell: annual BMI recording fell 8.9 pp (England +5.1 pp) to 71.5%, and blood pressure checks fell 6.8 pp (England +4.4 pp) to 72.4%. Dementia registers fell 5.1% (England +6.0%). Conversely, heart failure reviews rose 70.9% (England +8.7%) to 83.8%, and learning disability registers rose 13.6% (England +5.4%). These divergent trends could reflect uneven recall capacity, to verify through clinic audits.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
BMI record (SMI)
BP control, 80+
Asthma reviews
BP check (SMI)
Dementia register
Heart failure reviews
Breast screening (53-70)
QRISK statin treatment
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Medway (LAD) | Asset | PCN | Medway (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 26 (749 beds) | n/a | Schools (catchment) | 135 | n/a |
| Children's centres | 9 | 19 | Places of worship | 44 | 110 |
| Libraries | 5 | 9 | Food banks (VCS) | 7 | 6 |
| Homelessness support (VCS) | 1 | 9 | Day centres (VCS) | 6 | 29 |
| Children and young people (VCS) | 27 | 65 | Carers support groups (VCS) | 10 | 22 |
| Primary schools (LA maintained) | 7 | 17 | Primary academies | 28 | 56 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Structured asthma annual review recall
On the asthma register of 2,084 patients, annual review coverage fell 7.1% over 2023 to 2025 to 61.5% (England 65.7%, +4.4%; Medway (LAD) 62.6%, -3.4%), leaving 803 patients unreviewed. For discussion: run a single-template asthma review recall offering after-school slots and checking inhaler prescribing alongside second-hand smoke recording. Low cost, quick to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
Hypertension BP control and titration review
Across 5,238 hypertension patients, treatment to target is 59.5% (England 70.3%, Medway (LAD) 67.5%), recent BP recording is 81.3% (England 90.0%), and age 80+ control fell 10.7% to 62.8% (England 81.2%). Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Option 3
Combined SMI physical health check clinics
On the SMI register of 323 patients, 12-month BMI recording fell 8.9 pp to 71.5% (England 82.1%, +5.1 pp), BP checks fell 6.8 pp to 72.4% (England 83.4%, +4.4 pp), and alcohol recording fell 2.1 pp to 76.2% (England 81.8%). Moderate effort to run.
Evidence base: the SMI register is the cohort for the annual physical health check; the alcohol record is the delivery measure for alcohol screening and brief intervention.
Policy anchor: Mental Health Investment Standard; NHS alcohol care teams and the From Harm to Hope strategy.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Paediatric and family service review (p2) | Aged 0-17 | Medium Term Planning Framework 2026 · Neighbourhood health framework | PCN |
| Targeted outreach and reconciliation (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI physical check recall audit (p4) | Record of BMI in the last 12 months for patients on the MH register (denominator incl. PCAs) | MHIS · From Harm to Hope | PCN |
| Hypertension recall and titration audit (p5) | Last BP reading of patients (80+ yrs with hypertension) in the last 12 months is <= 150/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Preschool booster recall audit (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cancer register and referral review (p7) | Cancer: QOF prevalence | Core20PLUS5, 75% stage 1–2 by 2028 | PCN |
| Option 1 · Structured asthma annual review recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) · Patients with Asthma (6-19 yrs): Second-hand smoking status recorded in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
| Option 2 · Hypertension BP control and titration review (p12) | Hypertension register · Hypertension patients with a recent BP reading · Hypertension patients treated to target | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Option 3 · Combined SMI physical health check clinics (p12) | Severe mental illness register · SMI register with a BMI recorded in the last 12 months · Record of BMI in the last 12 months for patients on the MH register (denominator incl. PCAs) | MHIS · From Harm to Hope | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
